Autor(es):
Fangueiro, JF ; Andreani, T ; Egea, MA ; Garcia, ML ; Souto, SB ; Silva, AM ; Souto, EB
Data: 2014
Identificador Persistente: http://hdl.handle.net/10400.23/576
Origem: Repositório Científico do Hospital de Braga
Projeto/bolsa:
info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F80335%2F2011/PT;
info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F60640%2F2009/PT;
info:eu-repo/grantAgreement/FCT/5876-PPCDTI/113100/PT
;
Assunto(s): Olho/metabolismo; Nanopartículas; Lípidos; Soluções Oftálmicas
Descrição
In the present study we have developed lipid nanoparticle (LN) dispersions based on a multiple emulsion technique for encapsulation of hydrophilic drugs or/and proteins by a full factorial design. In order to increase ocular retention time and mucoadhesion by electrostatic attraction, a cationic lipid, namely cetyltrimethylammonium bromide (CTAB), was added in the lipid matrix of the optimal LN dispersion obtained from the factorial design. There are a limited number of studies reporting the ideal concentration of cationic agents in LN for drug delivery. This paper suggests that the choice of the concentration of a cationic agent is critical when formulating a safe and stable LN. CTAB was included in the lipid matrix of LN, testing four different concentrations (0.25%, 0.5%, 0.75%, or 1.0%wt) and how composition affects LN behavior regarding physical and chemical parameters, lipid crystallization and polymorphism, and stability of dispersion during storage. In order to develop a safe and compatible system for ocular delivery, CTAB-LN dispersions were exposed to Human retinoblastoma cell line Y-79. The toxicity testing of the CTAB-LN dispersions was a fundamental tool to find the best CTAB concentration for development of these cationic LN, which was found to be 0.5wt% of CTAB.
